SteveAMorrisMD

Pain Medicine

Physician

Are you Dr. Morris?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Connect with colleagues in the same hospital or clinic
You already have 27 invites waiting!
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

Dr. Steve Morris, MD is a board certified anesthesiologist in Knoxville, Tennessee. He is currently licensed to practice medicine in Tennessee.

University of Tennessee Medical Center at KnoxvilleResidency, Anesthesiology, 1978 - 1981
University of Tennessee Medical Center at KnoxvilleInternship, Transitional Year, 1977 - 1978
University of Tennessee Health Science Center College of MedicineClass of 1977

PubMed

64 citations
Demonstration of an activation regulated NF-κB/I-κBα complex in human platelets
Fengqi Liu, Steve A. Morris, Jerry L. Epps, Roger C. Carroll> ;Thrombosis Research. 2002 May 15
6 citations
Synergistic outside-in regulation of platelet activation by GPIIb/IIIa ligand-induced conformation and oligomerization.
Xiao-fen Wang, Fengqi Liu, Steve A. Morris, Roger C. Carroll> ;Thrombosis Research. 2001 Nov 15
15 citations
Lotrafiban: an oral platelet glycoprotein IIb/IIIa blocker.
Fengqi Liu, Robert M. Craft, Steve A. Morris, Roger C. Carroll> ;Expert Opinion on Investigational Drugs. 2000 Nov 1
12 citations
Anesthetic Management of Patients Receiving Calculus Therapy with a Third-Generation Extracorporeal Lithotripsy Machine
Michael P. Hosking, Steve A. Morris, Frederick A. Klein, Cindy Dobmeyer-Dittrich> ;Journal of Endourology. 1997 Oct 1
22 citations
The effect of LPS on cytokine synthesis and lung neutrophil influx after hepatic ischemia/reperfusion injury in the rat
Joan B. Carrick, Octacillio Martins, Carolyn C. Snider, Norman D. Means, Blaine L. Enderson, Scott B. Frame, Steve A. Morris, Michael D. Karlstad> ;The Journal of Surgical Research. 1997 Feb 15
Join now to see all

Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for Covalent Menin Inhibitor BMF-219 in Type 2 DiabetesDecember 14th, 2022
Biomea Fusion Announces Appointment of Steve Morris, M.D. As Chief Medical OfficerFebruary 1st, 2022
Biomea Fusion Announces Appointment of Steve Morris, M.D. As Chief Medical OfficerFebruary 1st, 2022
Join now to see all